Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment ‘Enavogliflozin’ and Roadmap to Enter 50 Countries by 2030
Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing blood glucose levels and safety SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ — Daewoong Pharmaceutical (Daewoong), the South Korea-based global healthcare company, announced the phase III clinical trial results